Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis

Rheumatology

Volumn 47, Issue 1, 2008, Pages 22-30

  Zheng, Z H ^a   Li, X Y ^a   Ding, J ^a   Jia, J F ^a   Zhu, P ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Immunosuppression; Mesenchymal stem cells; Rheumatoid arthritis; T lymphocyte; Type II collagen

Indexed keywords

CD3 ANTIGEN; CD69 ANTIGEN; COLLAGEN TYPE 2; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; LIPOCORTIN 5; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; ARTICULAR CARTILAGE; BONE MARROW; CARTILAGE CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC DISEASE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; UPREGULATION;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHONDROCYTES; COCULTURE TECHNIQUES; COLLAGEN TYPE II; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37349104020     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem284     Document Type: Article

References (46)

1. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem calls. Science 1999;284:143-7.
2. Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998;79:1528-30.
3. Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem calls in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 2001;98:7841-5.
4. Shake JG, Gruber PJ, Baumgartner WA et al Mesenchymal stem cells implantation in a swine myocardial infarct model: Engraftment and functional effects. Ann Thorac Surg 2002;73:1919-25.
5. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees; Osteoarthr Cartilage 2002;10:199-206.
6. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48-3464-74.
7. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal model of suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-43.
8. Krampera M, Glennis S, Dyson J et al Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen specific T cells to their cognate peptide. Blood 2003;101:3722-9
9. Glennie S; Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy activated T cells. Blood 2005;105:2821-7.
10. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
11. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival In vivo. Exp Hematol 2002;30:42-8.
12. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem calls. Lancet 2004;363:1439-41.
13. Zappia E, Casazza S, Pedemonte E et al. Masenchymal stem calls ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755-61.
14. Park SH, Min DJ, Cho ML et al. Shift toward T helper 1 cytokines by type II collagen-reactive T cells patients with rheumatoid arthritis. Arthritis Rheum 2001;44:561-9.
15. Fox DA. The role of T calls in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997;40:598-609.
16. Miossec P. Are T cells in rheumatoid synovium aggressors or bystanders? Curr Opin Rheumatol 2000;12:181-5.
17. Maldonado A, Mueller YM, Thomas P, Bojczuk P, O'Connors C, Katsikis PD. Decreased effector memory CD45RA+CD62L- CD8+ T cells and increased central memory CD45RA- CD62L+ CD8+ T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Res Ther 2003;R91-6.
18. Kang YM, Zhang X, Wagner UG, Yang H, Beckenbaugh RD, Kurtin PJ. CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 2002;195:1325-36.
19. Sekine T, Kato T, Masuko-Hongo K et al. Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:446-50.
20. Kim WU, Kim KJ. T cell proliferative response to type II collagen in the inflammatory process and joint damage in patients with rheumatoid arthritis. J Rheumatol 2005;32;225-30.
21. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8 + T cells into cytotoxic CD8 + T cells secreting Th1 or Th2 cytokines. Immunity 1995;2:271-9.
22. Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T calls induce production of interleukin-1 beta by monocytic cells: A possible role of CD69. Eur Cytokine Netw 1993;4:15-23.
23. Kong YY, Feige U, Sarosi I et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotagerin ligand. Nature 1999;402:304-9.
24. Benoist C, Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res 2000;2:90-4.
25. Wahl SM, Malone DG, Wilder RL. Spontaneous production of fibroblast-activating factor(s) by synovial inflammatory calls: A potential mechanism for enhanced tissue destruction. J Exp Med 1985;161:210-22.
26. Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 2006;6:13-9.
27. Toussirot E, Wendling D. The use of TNF-α blocking agents in rheumatoid arthritis: An overview. Expert Opin Pharmacother 2004;5:581-94.
28. Van den Bosch F, Russell A, Keystone EC et al. rHUIL-4 in subjects with active rheumatoid arthritis (RA): A phase I dose escalating safety study. Arthritis Rheum 1998;41(Suppl 9):S56.
29. Maini RN, Paulus H, Breedveld FC et al. rHUIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study. Arthritis Rheum 1997;40(Suppl 9):S224.
30. Benya PD, Padilla SR, Nimni ME. Independent regulation of collagen types by chondrocytes during the loss of differentiated function in culture. Cell 1978;15:1313-21.
31. Tropel P, Noël D, Platet N, Legrand P, Benabid AL, Berger F. Isolation and characterisation of mesenchymal stem calls from adult mouse bons marrow. Exp Cell Res 2004;295:395-406.
32. Zhu P, Li XY, Wang HK et al. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol 2007;122:75-84.
33. Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-72.
34. Chomarat P, Vannier E, Dechanet J et al. Balance of IL-1 receptor antagonist/IL-1b in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154:1432-9.
35. Katsikis PD, Chu C-Q, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
36. Van Roon JAG, Lafeber FPJG, Bijlsma JWJ. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001;44:3-12.
37. Van Roon JAG, Van Roy JLAM, Duits A, Lafeber FPJG, Bijlsma JWJ. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. Ann Rheum Dis 1995;54:836-40.
38. Isomäki P, Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 1997;29:499-507.
39. Van Roon JAG, van Roy JLAM, Gmelig-Meyling FHJ, Lafeber FPJG, Bijlsma JWJ. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996;39:829-35.
40. Jantunen E, Luosujärvi R. Stem cell transplantation in autoimmune diseases: An update. Ann Med 2005;37:533-41.
41. Weyand CM, Goronzy JJ. Stem cell aging and autoimmunity in rheumatoid arthritis. Trends Mol Med 2004;10:426-33.
42. Jones EA, English A, Henshaw, K, Kinsey SE, Markham AF, Emery P. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum 2004;50:817-27.
43. Tse WT, Pendleton JD, Boyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75:389-7.
44. Le Blanc K, Tämmik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-6.
45. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992;89:7375-9.
46. Wahl SM, Allen JB, Costa GL, Wong HL, Desch JR. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor β. J Exp Med 1993;77:225-30.